April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Flexible Multimodal Approach To Eye Melanoma: Patterns Of Care And Related Complications
Author Affiliations & Notes
  • Federica Genovesi-Ebert
    UO Chirurgia Oftalmica,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Maria-Grazia Fabrini
    Radiotherapy Department,,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Franco Perrone
    Medical Physisics,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Emanuele Di Bartolo
    UO Chirurgia Oftalmica,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Federica Cresti
    UO Chirurgia Oftalmica,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Carlo Greco
    Radiotherapy Department,,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Stanislao Rizzo
    UO Chirurgia Oftalmica,
    Azienda Ospedaliera Universitaria Pisana, Pisa, Italy
  • Footnotes
    Commercial Relationships  Federica Genovesi-Ebert, None; Maria-Grazia Fabrini, None; Franco Perrone, None; Emanuele Di Bartolo, None; Federica Cresti, None; Carlo Greco, None; Stanislao Rizzo, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3269. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Federica Genovesi-Ebert, Maria-Grazia Fabrini, Franco Perrone, Emanuele Di Bartolo, Federica Cresti, Carlo Greco, Stanislao Rizzo; Flexible Multimodal Approach To Eye Melanoma: Patterns Of Care And Related Complications. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3269.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To evaluate the efficacy and safety of a flexible radiotherapy approach for uveal malignant melanomas (UMM)

Methods: : A retrospective analysis was performed on a series of 100 consecutive patients treated between 2003 and 2010 in a single institution. Main outcome measures were survival rate, enucleation rate, local tumor control, visual outcomes and complications. The treatment was planned depending on tumor size and location, using a multimodal range of options such as: brachytherapy plaque (Ruthenium 106 and/or Iodine 125), stereotactic irradiation (SRS).Brachytherapy was the treatment of choice in small- (< 3mm) and medium-sized (3 -10 mm) tumors. A 106-Ru plaque was used for T1-T2 lesions with a single administration with a prescription dose of 100-120 Gy to tumor apex. For medium-sized UMM a single fraction with a 125-I plaque was used with a prescription dose of 85 Gy to COMS point for lesions < 5 mm, and to tumor apex for larger lesions. In selected cases, two subsequent fractions with 106-Ru and a 125-I plaque were used to keep the scleral dose with acceptable toxicity levels while ensuring an optimal dose coverage. In the presence of large (>10 mm) tumors the treatment of choice was SRS with a dose of 30 Gy in a single fraction. A sequential brachytherapy treatment was performed 6 weeks after SRS with a prescription dose of 45 Gy to COMS point.Transpupillary thermotherapy and intravitreal injection of bevacizumab were used as adjunctive therapies.

Results: : Median follow-up was 35.4 months. Mean 5-year overall survival was 95.3%. Local recurrence rate 3.7%. Vision preservation achieved in 84% of cases.Treatment-related major complications occurred in 6% of cases (2 severe glaucomas, 1 scleral necrosis, 2 radiation retinopathy, 1 optic neuropathy). Enucleation was performed in 4 patients due to uncontrolled neovascular glaucoma (2 eyes) or local recurrence ( 2 cases).Tumor reduction was : large UMM 14.0 %, medium UMM 40.5 %,small UMM 66%.

Conclusions: : The flexible approach to uveal melanomas achieves a high local tumor control rate with a low complication rate by reducing the over-irradiation of healthy tissues. The survival rates appear similar to previously published data

Keywords: melanoma • radiation therapy • oncology 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×